The increased infection rate of MM patients undergoing anti-CD38 therapies is due to the CD38 expression on both malignant and healthy plasma cells and on other immune effector cells (e.g., NK cells), which leads to a reduction of polyclonal Igs and innate immune cell response [57,99]. The gene discussed is CD38; the disease is Miyoshi myopathy.